Proteins with allulose-3-epimerase activity and their applications
By providing a protein and carrier system with ketose-3-epimerase activity, the conversion rate and yield of allulose are improved, solving the problem of low conversion rate and volumetric yield of ketose-3-epimerase in the prior art, and meeting the demand of the food and beverage industry for low-calorie sweeteners.
Patent Information
- Application Number
- CN202611251143.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2012-11-15
- Filing Date
- 2013-09-27
- Publication Date
- 2026-11-17
AI Technical Summary
In existing allulose preparation technologies, the conversion rate and volumetric yield of ketose-3-epimerase are low, making it difficult to meet the demand of food and beverage manufacturers for high-sweetness, low-calorie sweeteners.
A protein with ketose-3-epimerase activity is provided, which is converted into allulose under specific conditions by contact with fructose, and can be efficiently expressed and immobilized by a vector and host cell system to improve conversion rate and yield.
This study achieved high conversion and high volumetric yield of allulose, meeting the demand for low-calorie sweeteners in the food and beverage industry and providing an efficient method for allulose synthesis.
Smart Images

Figure CN123107979A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a protein having ketose-3-epimerase activity, and a nucleic acid molecule encoding said protein. The invention also relates to a vector and a host cell containing said nucleic acid molecule. Furthermore, the invention relates to a method for synthesizing allulose from said protein, and allulose produced in this manner. Background Technology
[0002] Allulose is a "zero-calorie" sweetener with a sweetness considered similar to glucose. It also possesses filling and browning properties similar to other sugars. The primary target market for allulose is food and beverage manufacturers, who currently use glucose, fructose, or high-fructose corn syrup in their products and are seeking to significantly reduce calories without significantly altering other properties imparted by the sugar composition, such as filling, browning, texture, and sweetness.
[0003] In the United States, allulose is not generally considered a GRAS (Generally Recognized As Safe) substance, but there is currently one pending GRAS notification (GRN400). Allulose is found in processed sugarcane and beet molasses, steam-processed coffee, wheat plant products, and high-fructose corn syrup. The typical total daily intake of allulose is estimated to be more than 0.2 grams per day. D-Allulose is the C-3 epimer of D-fructose, and the structural difference between allulose and fructose means that allulose cannot be metabolized by the human body, thus having zero calories. Because allulose contains no calories, it is considered a promising candidate sweetener, and is claimed to retain properties similar to typical monosaccharides while providing sweetness.
[0004] Ketoose-3-epimerase can interconvert fructose and allulose. US Patent No. 8030035 and PCT Publication No. WO2011 / 040708 disclose the reaction of a protein from Agrobacterium tumefaciens with allulose-3-epimerase activity with D-fructose to produce D-allulose (another name for allulose).
[0005] U.S. Patent Publication No. 2011 / 0275138 discloses a ketose-3-epimerase from a Rhizobium genus microorganism. This protein exhibits high specificity for D- or L-pentylulose and D- or L-hexylulose, particularly D-fructose and D-allulose. The document also discloses a method for producing ketoses using the protein.
[0006] Korean Patent No. 100832339 discloses a strain of *Sinorhizobium* YB-58 that can convert fructose into allulose, and discloses a method for producing allulose using the fungal body of *Sinorhizobium* YB-58 strain.
[0007] Korean patent application No. 1020090098938 discloses a method for producing allulose using Escherichia coli, wherein the Escherichia coli expresses a polynucleotide encoding allulose-3 isomerase.
[0008] The purpose of this invention is to improve existing techniques for preparing allulose. Specifically, it aims to provide a ketose-3-epimerase with higher conversion and volumetric yield in whole-cell systems than previously reported. Summary of the Invention
[0009] This invention originates from the identification and characterization of three ketose-3-epimerases, whose exemplary amino acid sequences are shown in sequences numbered 2, 4, and 6, respectively. These ketose-3-epimerases can be used to convert fructose into allulose. Previously, these proteins had been identified as hypothetical proteins or as possessing tagatose isomerase activity. However, the inventors have now surprisingly discovered that these enzymes possess allulose-3-epimerase activity.
[0010] A first aspect of the present invention provides a protein containing a polypeptide sequence having at least 70% sequence identity with sequence number 2, sequence number 4 or sequence number 6, characterized in that the protein has ketose-3-epimerase activity.
[0011] For convenience, the polypeptide sequence has at least 80%, 90%, 95%, or 99% sequence identity, or 100% sequence identity, with respect to sequence number 2, sequence number 4, or sequence number 6.
[0012] Preferably, the polypeptide sequence includes sequence number 13.
[0013] Preferably, the protein is immobilized in a solid matrix.
[0014] A second aspect of the present invention provides the use of the protein of the first aspect of the present invention for the synthesis of allulose.
[0015] A third aspect of the present invention provides a nucleic acid molecule comprising a polynucleotide sequence encoding the protein described in the first aspect of the present invention.
[0016] Preferably, the nucleic acid molecule comprises a polynucleotide sequence, wherein: i) The polynucleotide sequence has at least 70%, 80%, 90%, 95%, or 99% sequence identity, or 100% sequence identity, with sequence number 5, 1, or 3; or ii) Hybridization of the polynucleotide sequence under highly stringent conditions yields a polynucleotide having a sequence complementary to the sequence shown in number 5, number 1, or number 3.
[0017] A fourth aspect of the present invention provides a carrier, characterized in that the carrier comprises the nucleic acid molecule described in the third aspect of the present invention.
[0018] A fifth aspect of the present invention provides a host cell, characterized in that the host cell comprises the recombinant nucleic acid molecule described in the third aspect of the present invention.
[0019] For convenience, the host cell is a yeast, bacteria or other microorganism, or a culture of a mammal, plant or other cell.
[0020] Preferably, the host cell is Escherichia coli.
[0021] A sixth aspect of the present invention provides an allulose made from the protein described in the first aspect of the present invention.
[0022] A seventh aspect of the present invention provides a method for manufacturing allulose, comprising: i) Provide the protein as described in the first aspect of the present invention; and ii) Contacting the protein with a fructose matrix under conditions that allow the fructose matrix to be converted into allulose. The present invention also provides a method for manufacturing allulose, the method comprising: contacting the protein described in the first aspect of the present invention with a fructose matrix under conditions that allow the fructose matrix to be converted into allulose.
[0023] Preferably, the protein is present in the host cell.
[0024] Alternatively, the protein may be in isolated form.
[0025] For convenience, these conditions include maintaining the protein and fructose matrix between 25°C and 75°C, preferably between 50°C and 60°C, more preferably between 52°C and 55°C, and even more preferably 55°C.
[0026] Preferably, the conditions include maintaining the protein and fructose matrix between pH 4 and pH 10.
[0027] Preferably, the conditions include maintaining the fructose matrix concentration between 75% and 95% (W / V).
[0028] An eighth aspect of the present invention provides a nucleic acid molecule containing a polynucleotide sequence, wherein: i) The polynucleotide sequence has at least 70% sequence identity with sequences numbered 5, 1, or 3; or ii) The polynucleotide sequence is hybridized under highly stringent conditions to obtain a polynucleotide having a sequence complementary to the sequence shown in number 5, number 1 or number 3.
[0029] This nucleic acid molecule encodes a polypeptide with ketose-3-epimerase activity. As described in one aspect of the invention, the nucleic acid molecule can be in an isolated form.
[0030] A ninth aspect of the present invention provides a host cell comprising a recombinant nucleic acid molecule, said nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide having ketose-3-epimerase activity, wherein the polynucleotide sequence is characterized in that: i) It has at least 70% sequence identity with sequence number 5, number 1, or number 3; or ii) Hybridization under highly stringent conditions yields a polynucleotide having a sequence complementary to the sequence shown in number 5, number 1, or number 3.
[0031] A tenth aspect of the present invention provides a carrier comprising a nucleic acid molecule, the nucleic acid molecule comprising a polynucleotide encoding a polypeptide having ketose-3-epimerase activity, wherein the polynucleotide sequence is characterized in that: i) It has at least 70% sequence identity with sequence number 5, number 1, or number 3; or ii) Hybridization under highly stringent conditions yields a polynucleotide having a sequence complementary to the sequence shown in number 5, number 1, or number 3.
[0032] The eleventh aspect of the present invention provides a method for preparing allulose, the method comprising the following steps: i) Provides a vector containing a nucleic acid molecule having a polynucleotide sequence encoding a protein having ketose-3-epimerase activity, wherein the polynucleotide sequence is characterized in that: a) it has at least 70% sequence identity with sequences numbered 5, 1, or 3, or b) it hybridizes under highly stringent conditions to obtain a polynucleotide having a sequence complementary to the sequence shown in sequence numbered 5, 1, or 3; ii) Synthesize proteins with ketose-3-epimerase activity encoded by polynucleotide sequences; iii) Contact fructose with a protein possessing ketose-3-epimerase activity, and maintain the fructose and protein under conditions that allow for the conversion of fructose to allulose; and iv) At least partially purify the allulose produced in step iii).
[0033] In this document, the terms “polypeptide,” “peptide,” and “protein” are used interchangeably to refer to polymers of amino acid residues. These terms also apply to amino acid polymers with one or more modified amino acid residues or residues that are not naturally occurring, such as naturally occurring amino acids and their corresponding artificial chemical analogs. Polypeptides are not necessarily in an “isolated” form, meaning they are not necessarily located outside their natural surrounding components.
[0034] The term "amino acid" as used in this article refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimics that have similar functions to naturally occurring amino acids. Naturally occurring amino acids refer to those encoded by the genetic code, as well as amino acids that are modified after translation in cells (e.g., hydroxyproline, γ-carboxyglutamic acid, O-phosphoserine). The phrase "amino acid analog" refers to a compound that has the same basic chemical structure (α-carbon bonded to hydrogen, carboxyl, amino, R group) as naturally occurring amino acids, but has a modified R group or a modified backbone (e.g., serine, leucine, methionine sulfoxide, methionine methylsulfonium). The phrase "amino acid mimic" refers to a class of compounds that have a different structure than naturally occurring amino acids but have similar functions. It should be understood that, due to the degeneracy of the genetic code, nucleic acid molecules encoding specific polypeptides may have a series of polynucleotide sequences. For example, the codons GCA, GCC, GCG, and GCT all encode the amino acid alanine.
[0035] Using BLASTP algorithm version 2.2.2 (Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402) with default parameters, the percentage "identity" of two sequences can be determined. In particular, the BLAST algorithm can be evaluated online via the URL http: / / www.ncbi.nlm.nih.gov / blast / .
[0036] As used herein, the term "ketose-3-epimerase activity" refers to an enzyme capable of catalyzing the stereochemical transformation of ketoses, particularly the conversion of fructose to allulose. For example, in one embodiment, "ketose-3-epimerase activity" refers to the ability of each milligram of added enzyme (0.1 units / mg) to increase the rate of fructose-allulose interconversion by at least 10 μmol / min compared to a reaction mixture without the enzyme under the same conditions. In other embodiments, an increase in the rate of fructose-allulose interconversion of at least 0.05 units / mg or 0.2 units / mg is considered to constitute "ketose-3-epimerase activity." A suitable method for determining the enzyme's activity in converting D-fructose to allulose is provided below. A reaction mixture containing 1 mL of D-fructose (50 g / L), Tris-HCl buffer (50 mM, pH 8.0), and 0.5 μM of enzyme is incubated at 55ºC for 2 minutes. The reaction is stopped by boiling after 10 minutes. The amount of D-allulose obtained was determined by high performance liquid chromatography (HPLC). One unit of enzyme activity was defined as the amount of enzyme that catalyzes the formation of 1 μmol of D-allulose per minute at pH 8.0 and 55 °C (J. Agric. Food Chem. 2011, 59, 7785-7792).
[0037] The terms “gene,” “polynucleotide,” and “nucleic acid molecule” are used interchangeably in this document to refer to polynucleotide polymers. Nucleic acid molecules may contain naturally occurring nucleic acids (DNA or RNA) or artificial nucleic acids, such as peptide nucleic acids, morpholine and locked nucleic acids, as well as glycol nucleic acids and threonine nucleic acids.
[0038] The term "nucleotide" as used in this article refers to naturally occurring nucleotides, as well as synthetic nucleotide analogs that can be recognized by cellular enzymes.
[0039] As used in this article, the term "vector" refers to any natural or artificial construct containing a nucleic acid molecule that can be catalyzed by cellular transcriptases and / or translatases. Example vectors include plasmids, viruses (including bacteriophages), granules, artificial chromosomes, or transposons.
[0040] As used in this article, “host cell” refers to any biological cell that can be cultured in a culture medium and used to express recombinant genes. These host cells can be eukaryotic or prokaryotic cells, microbial cells such as bacterial cells, or cells derived from a cell line (such as an immortalized mammalian cell line).
[0041] As used herein, the term "highly stringent conditions," when referring to hybridization conditions, means: initial washing at approximately 6 times the amount of SSC and 1% SDS at 65°C for 10 minutes with approximately 20% (v / v) formamide prepared in 0.1 times the amount of SSC, followed by washing at 65°C with 0.2 times the amount of SSC and 0.1% SDS. Under such highly stringent conditions as described in this specification, hybridization techniques using known nucleic acids as probes will recognize structurally similar nucleic acids, which is a well-known technique in the art.
[0042] The term "alulose" as used in this article refers to a monosaccharide having the structure shown in formula (I). It is also known as "D-alulose".
[0043] Formula (I)
[0044] As used herein, the term "fructose" refers to a monosaccharide having the structure shown in Formula (II). Examples of fructose matrices include, but are not limited to, crystalline fructose and crystalline fructose molasses. As used herein, the term "crystalline fructose molasses" refers to the process fluid generated during the crystallization of fructose from the amorphous portion of the mother liquor.
[0045] Equation (II)
[0046] As used herein, the term "recombinant" refers to a nucleic acid molecule or polypeptide produced through artificial intervention in a non-natural environment. Examples of recombinant polypeptides include a first polypeptide isolated from other polypeptides, or a first polypeptide linked to a second polypeptide sequence via peptide bonds, wherein the amino acid sequence of the second polypeptide differs from any polypeptide associated with the first polypeptide in nature. Attached Figure Description
[0047] Figure 1 The image shows the amino acid sequence (sequence number 2) of the ketose-3-epimerase obtained from Clostridium scindens as described in an embodiment of the present invention.
[0048] Figure 2 The image shows the amino acid sequence (sequence number 4) of a ketose-3-epimerase obtained from Clostridium hylemonae, as in another embodiment of the present invention.
[0049] Figure 3 The image shows the amino acid sequence (Sequence Number 6) of a ketose-3-epimerase obtained from Desmospora sp. as in another embodiment of the present invention.
[0050] Figure 4The amino acid sequence (Sequence No. 8) of a previously known xylose isomerase obtained from Clostridium celluloyticum is shown.
[0051] Figure 5 It shows the result of Figures 1 to 3 The sequences of the three ketose-3-epimerases shown are compared with those of the three previously known ketose-3-epimerases, with the intact residues highlighted.
[0052] Figure 6 The figure shows the conversion rate curve of fructose to allulose by transformed Escherichia coli, wherein the conversion of Escherichia coli expresses an enzyme described in the embodiments of the present invention and a control.
[0053] Figure 7 The code shown is Figure 4 The amino acid sequence shown is the optimized gene sequence (sequence number 7), and a comparison between the optimized sequence and the original sequence.
[0054] Figure 8 The code shown is Figure 3 The amino acid sequence shown is the optimized gene sequence (sequence number 5), and a comparison between the optimized sequence and the original sequence.
[0055] Figure 9 The code shown is Figure 1 The amino acid sequence shown is the optimized gene sequence (Sequence No. 1), and a comparison between the optimized sequence and the original sequence.
[0056] Figure 10 The code shown is Figure 2 The amino acid sequence shown is the optimized gene sequence (sequence number 3), and a comparison between the optimized sequence and the original sequence.
[0057] Figure 11 The diagram shows the conversion of fructose matrix to allulose by transformed Escherichia coli. The conversion of Escherichia coli was carried out on a scale of 18 liters to express an enzyme (ketose-3-epimerase obtained from Desmospora sp.) as described in the embodiments of the present invention.
[0058] Figure 12 The graph shows the allulose conversion rate catalyzed by the enzymes (CH P3E, CS P3E and DS P3E) of the present invention and a known ketose-3-epimerase (CC P3E).
[0059] Figure 13 The graph shows the conversion rate of allulose catalyzed by DSP3E in a 30 mL fixed-bed reactor filled with A568 resin.
[0060] Figure 14 The graph shows the conversion rate of allulose catalyzed by DSP3E in a 300 mL fixed-bed reactor filled with A568 resin.
[0061] Figure 15 The amino acid sequence shown is that of an artificial variant of the naturally occurring ketose-3-epimerase obtained from Desmospora sp. (sequence number 13).
[0062] Brief description of the sequence list Sequence number 1 shows the gene sequence encoding the ketose-3-epimerase obtained from Clostridium scintillans (optimized for expression in Escherichia coli).
[0063] Sequence number 2 shows the amino acid sequence of the ketose-3-epimerase encoded by the gene sequence number 1.
[0064] Sequence number 3 shows the gene sequence encoding the ketose-3-epimerase obtained from Clostridium halys (optimized for expression in Escherichia coli).
[0065] Sequence number 4 shows the amino acid sequence of the ketose-3-epimerase encoded by the gene sequence number 3.
[0066] Sequence number 5 shows the gene sequence encoding the ketose-3-epimerase derived from Desmospora sp. 8437 (optimized for expression in E. coli).
[0067] Sequence number 6 shows the amino acid sequence of the ketose-3-epimerase encoded by the gene sequence number 5.
[0068] Sequence number 7 shows the gene sequence encoding ketose-3-epimerase obtained from Clostridium cellulosum (optimized for expression in Escherichia coli).
[0069] Sequence number 8 shows the amino acid sequence of the ketose-3-epimerase encoded by the gene sequence number 7.
[0070] Sequence number 9 shows the naturally occurring gene sequence encoding ketose-3-epimerase obtained from Clostridium scintillans.
[0071] Sequence number 10 shows the naturally occurring gene sequence encoding ketose-3-epimerase obtained from Clostridium helixol.
[0072] Sequence number 11 shows the naturally occurring gene sequence encoding the ketose-3-epimerase derived from Desmospora sp. 8437.
[0073] Sequence number 12 shows the naturally occurring gene sequence encoding ketose-3-epimerase obtained from Clostridium cellulose.
[0074] Sequence number 13 shows the amino acid sequence of an artificial variant of the ketose-3-epimerase of Desmospora sp. 8437. Detailed Implementation
[0075] In general, the present invention relates to a protein comprising a polypeptide having an amino acid sequence as indicated by sequence number 2, 4, or 6. The source organisms of the polypeptides with sequence numbers 2, 4, and 6 are shown in Table 1.
[0076] Table 1
[0077] However, in other embodiments, the polypeptide sequence is not completely identical to that shown in sequence numbers 2, 4, and 6, but has at least 70% sequence identity with them. Preferably, the polypeptide sequence has at least 80%, 90%, 95%, or 99% sequence identity, or 100% sequence identity, with sequence numbers 2, 4, or 6.
[0078] For example, in one embodiment, the polypeptide sequence includes sequence number 13, which has 89% sequence identity with sequence number 6. This polypeptide sequence possesses ketose-3-epimerase activity.
[0079] Therefore, in some embodiments, one or more amino acids of the peptide are deleted or substituted with different amino acids, preferably with similar amino acids. Similar amino acids are those with related properties in their side chain portions, and naturally occurring amino acids can be categorized into the following groups: Groups with basic side chains: lysine, arginine, histidine. Groups with acidic side chains: aspartic acid and glutamic acid. Groups with uncharged polar side chains: asparagine, glutamic acid, serine, threonine, and tyrosine. Groups with nonpolar side chains: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and cysteine. Therefore, it is preferable to substitute amino acids having these groups.
[0080] Generally, peptides are preferred to have chemical properties consistent with naturally occurring peptides (although they can also be synthesized in vitro). However, in some other embodiments, the peptides are peptide pseudomorphs, i.e., peptides modified in a non-natural manner. Such peptide pseudomorphs include those in which naturally occurring amino acids are replaced with synthetic amino acids and / or the peptide backbone is modified. For example, in some embodiments, peptide bonds are replaced with reverse peptide bonds to generate a backward-facing peptide pseudomorph (see Méziére et al., J Immunol. 1997 Oct 1;159(7):3230-7, included in this document). Alternatively, amino acids are linked by covalent bonds rather than peptide bonds, but the amino acid residues forming the polymer chain maintain their spacing and orientation.
[0081] All such modified and unmodified polypeptides in this invention possess ketose-3-epimerase polymerase activity. That is, the purified or expressed proteins in host cells can catalyze the conversion of fructose to allulose. Suitable conditions for testing ketose-3-epimerase activity are shown in Example 1.
[0082] The polypeptides of this invention may be contained within a whole cell, or may be isolated proteins, partially purified proteins, or immobilized proteins. Protein purification may be performed using standard methods, such as cell disruption and filtration. Other standard methods are also known to those skilled in the art.
[0083] Embodiments of the present invention provide a nucleic acid molecule comprising a polynucleotide sequence encoding a protein, wherein the amino acid sequence of the protein has at least 70% sequence identity with sequences numbered 2, 4, or 6, and the protein possesses ketose-3-epimerase activity. For example, in one embodiment, the nucleic acid molecule contains a sequence encoding a polypeptide sequence numbered 13.
[0084] In addition to the sequence specifically encoding the protein described in this invention, the nucleic acid molecule may contain other sequences, such as primer sites, transcription factor binding sites, vector insertion sites, and sequences resistant to nucleolysis degradation (e.g., polyadenylated tails). The nucleic acid molecule may be DNA or RNA and may include synthetic nucleotides, provided that the polynucleotides can still be translated for the synthesis of the protein of this invention.
[0085] As described above, the amino acid sequence of the protein of the present invention may differ from the specific sequence disclosed herein. In a preferred embodiment, the nucleic acid molecule comprises a polynucleotide having a sequence numbered 1, 3, or 5, which is optimized for expression in *E. coli* host cells. In other embodiments, the polynucleotide sequence has at least 70% sequence identity with any of sequences numbered 1, 3, or 5 and encodes a protein having ketose-3-epimerase activity. Preferably, the polypeptide sequence has at least 80%, 90%, 95%, or 99% sequence identity, or 100% sequence identity, with one of sequences numbered 1, 3, or 5. In other embodiments, the nucleic acid molecule comprises a polynucleotide sequence hybridized under highly stringent conditions to obtain a polynucleotide having a sequence complementary to the sequences shown in sequences numbered 1, 3, or 5 and encodes a protein having ketose-3-isomerase activity. In some embodiments, a nucleic acid molecule is provided comprising a polynucleotide having a sequence numbered 9, 10, or 11, which is a naturally occurring sequence of the enzyme.
[0086] In some embodiments, the nucleic acid molecule is a component of a vector (such as a plasmid). In addition to the nucleic acid sequence described above, the plasmid may also contain other elements, such as a prokaryotic replication origin (e.g., the E. coli OR1 origin of replication), an autonomous replication sequence, a centromere sequence; a promoter sequence upstream of the nucleic acid sequence, a terminator sequence downstream of the nucleic acid sequence, an antibiotic resistance gene, and / or a secretion signal sequence. Vectors containing autonomous replication sequences may also be yeast artificial chromosomes.
[0087] In other embodiments, the vector is a virus, such as a bacteriophage, and in addition to the nucleic acid sequence of the present invention, it also includes nucleic acid sequences for bacteriophage replication, such as structural proteins, promoters, transcription promoters, etc.
[0088] The nucleic acid molecules of this invention can be used to transfect or transform host cells in order to synthesize the proteins of this invention. Suitable host cells include prokaryotic cells such as *Escherichia coli*, and eukaryotic cells such as yeast cells, or mammalian or plant cell lines. Transfection or transformation of host cells is performed using techniques known in the art, such as electroporation, calcium phosphate-based methods, gene gun techniques, or using viral vectors.
[0089] Following transfection, the nucleic acid molecules of this invention are transcribed and translated as needed. In some embodiments, the synthesized protein can be held in a host cell, and a culture of recombinant host cells can then be used. In other embodiments, the synthesized protein is extracted from the host cell by methods such as secreting the synthesized protein from the cell due to the presence of a secretion signal in the vector, or by lysing the host cell and purifying the resulting protein.
[0090] The protein of this invention catalyzes the conversion of fructose to allulose. In some embodiments, the protein is present in host cells and mixed with a fructose matrix, such as a fructose matrix buffered with borate, at a concentration of 1 to 1000 g / L under appropriate conditions (e.g., culture temperature from 25°C to 75°C, pH from 4 to 10) to form a conversion mixture. The conversion mixture may also contain a solvent and other optional co-solvents (other than water) such as ethanol, toluene, and methanol. The fructose matrix may also contain other sugars, such as glucose or sucrose. The protein catalyzes the conversion of the fructose matrix to allulose. In practice, not all fructose in the conversion mixture is converted to allulose, therefore a subsequent step of allulose extraction and purification by evaporation and crystallization is usually performed. Residual fructose in the mixture can be removed by yeast fermentation.
[0091] In other embodiments, the protein of the present invention is provided in a purified form and mixed with a fructose matrix and a suitable solvent for complete in vitro conversion. In one embodiment, the conditions are pH 4 to 10, temperature 30°C to 70°C, fructose concentration of 10% to 95% (w / v), and water as the solvent. Selectable fructose concentration ranges include, but are not limited to, 20% to 95%, 30% to 95%, 40% to 95%, 50% to 95%, 60% to 95%, 70% to 95%, and 75% to 95%. A particularly preferred fructose matrix concentration range is between 70% and 95%. In other preferred embodiments, the fructose concentration is 75% to 95%.
[0092] Ketoconversion reactions typically use a matrix concentration of 1% to 60% (weight / volume), preferably about 5% to 50%. A particular advantage of this invention is that the protein can be used for ketoconversion reactions under conventional operating conditions but with higher fructose concentrations than before. Therefore, a larger volumetric yield can be achieved using the protein of this invention.
[0093] In some embodiments, the proteins of the present invention are immobilized in a solid matrix. This has the advantage of a longer enzyme lifespan, the ability to be packed into small fixed-bed reactors, and greater tolerance to contaminants and fluctuations in process conditions. Example solid matrices include ion exchange resins and polymer encapsulation. In some embodiments, the proteins of the present invention are immobilized in Duolite A568 resin. In some embodiments, the proteins of the present invention are immobilized in a matrix using weakly basic ion exchange (i.e., based on the electrostatic interaction between the protein charge and the matrix charge, such as the resin charge). In other embodiments, the proteins are immobilized by non-specific binding to porous regions of a matrix, such as a resin.
[0094] In another embodiment, the present invention relates to a method for manufacturing allulose. The method includes the following steps.
[0095] 1) Provide a vector containing a nucleic acid molecule, wherein the nucleic acid molecule has at least 70% sequence identity with a sequence numbered 1, 3 or 5.
[0096] 2) Transform competent host cells using the vector.
[0097] 3) Optionally, the transformed host cells are cultured.
[0098] 4) Mix the transformed cells with the fructose matrix and maintain them under conditions that allow fructose to be converted into allulose.
[0099] 5) Purify the obtained allulose using standard methods in the art, such as evaporation and crystallization.
[0100] In other embodiments, step 4 is omitted. Instead, the protein encoded by the nucleic acid molecule is isolated from the transformed host cell and optionally immobilized in a matrix. The protein is then mixed with a fructose matrix and maintained under conditions that allow fructose to be converted into allulose. Step 5 is then performed. In other embodiments, step 2 is omitted, and the protein is also synthesized by in vitro translation. The protein is then isolated and mixed with the fructose matrix.
[0101] Allulose manufactured by the method described in this invention can be used in products for human and / or animal consumption. In some embodiments, the product may be a food, beverage, pharmaceutical, nutritional product, sports product, or cosmetic. For example, when the product is a food, the food may be selected from confectionery products, sweets, cereal products, baked goods, frozen dairy products, meat, dairy products, condiments, snack bars, soups, sauces, formulations, prepared foods, baby foods, dietary preparations, syrups, food coatings, dried fruits, seasonings, gravy, and jams / jelly. In some embodiments, the food may contain allulose manufactured by the method described in this invention as a coating or frosting on the product surface.
[0102] Optionally, when the product is a beverage product, the beverage product may be selected from carbonated beverages, non-carbonated beverages, fruit-flavored beverages, juices, tea, milk, coffee and similar beverages.
[0103] Example Example 1 In this embodiment, host cells were transformed to express one of three putative ketose-3-epimerases. The transformed host cells were co-cultured with a fructose matrix to test their ketose-3-epimerase activity.
[0104] materials 1 M pH 8 borate buffer: i) Dissolve 62 grams of boric acid in 1 liter of deionized water. ii) Adjust the pH to 8 using 10 M sodium hydroxide solution. iii) Store in a 1-liter bottle and then in a refrigerator at 4°C. Fructose matrix buffered with borate: i) Mix 970 g of liquid fructose (77% DS) with 50 mL of pH 8 borate buffer. ii) Add water to a final volume of 1 liter. iii) Adjust the pH to 8 using 5M sodium hydroxide solution. Expression medium LB - 4 x 2.8 L shake flasks with baffles: i) Dissolve 10g pancreatin, 7g sodium chloride and 10g yeast in 1 liter of deionized water. ii) Autoclaving method Three putative ketose-3-epimerase gene sequences and one control sequence were selected for synthesis and construction via GenscriptUSA. The putative ketose-3-epimerase sequences encode: i) The putative protein CLOSCI_02526 (sequence number 2) obtained from Clostridium scintillans ATCC 35704 (accession number ZP_02432281). ii) The putative protein CLOHYLEM_05645 (sequence number 4) obtained from Clostridium helixie DSM 15053 (accession number ZP_03778576.1). iii) by Desmospora sp. The D-tagatose 3-isomerase (sequence number 6) obtained from 8437 (accession number ZP_08466075).
[0105] The control sequence encodes the xylose isomerase protein (sequence number 8) obtained from Clostridium cellulose H10 (accession number YP_002505284).
[0106] The sequence optimized for expression in E. coli (see [link]). Figures 7 to 10 The genes were synthesized and constructed, and the resulting four genes were cloned into the expression vector pET15b. Other combinations of microorganisms and expression vectors known to those skilled in the art are expected to perform equally well.
[0107] Competent cells for transformation were prepared by inoculating 3 mL of lysogenic broth (LB) with *E. coli* BL21 (DE3) and incubating overnight at 37°C. This 3 mL culture was then inoculated into 300 mL of LB and incubated with shaking at 37°C until the cells reached an OD (600) of 0.7 to 1.0. The optical density (OD) in a 1 cm cuvette was measured at 600 nm using a typical spectrophotometer. The cells were cooled on ice for 10 min and then centrifuged at 7500 xg for 15 min at 4°C. The culture medium was discarded, and the cells were resuspended in 300 mL of cold water. The centrifugation was repeated, and the cells were resuspended in 150 mL of cold water. The centrifugation was repeated again, and the cells were resuspended in approximately 2 mL of cooled 10% sterile glycerol. The cells were centrifuged and resuspended in approximately 2 mL of cooled 10% sterile glycerol as described above. The suspension was aliquoted into sterile centrifuge tubes at 100 μl intervals and stored at -80°C.
[0108] Subsequently, the expression vector supplied by Genscript was used to transform competent *E. coli* BL21(DE3) via electroporation, and positive transformants were selected on LB agar containing ampicillin. One liter of LB agar was poured into four 2.8-liter baffled flasks and autoclaved. After cooling, 1 mL of 100 mg / L ampicillin was added to each flask under aseptic conditions, followed by 2–3 mL of the prepared overnight culture of competent cells (one flask per expression strain). Cells were grown at 37°C and 200 rpm for approximately 3 hours until the OD reached 0.8–1.5. One mL of freshly prepared 1 M isopropyl-β-D-1-thiogalactopyranoside solution was added to each flask, and the temperature was lowered to room temperature (25–30°C), inducing the reaction for approximately 5 hours. Cells were centrifuged at approximately 5000 xg for 30 minutes at 4°C, and the supernatant was decanted. Transfer the cell pellet to a pre-weighed 50 mL centrifuge tube and record the cell mass. Resuspend the cells in a few mL of sterile glycerol (10% by weight) and freeze at -80°C.
[0109] Whole cells were mixed with a borate-buffered fructose matrix and processed using the DP 1-4 method with calcium. 2+ The chromatographic column was analyzed using high-performance liquid chromatography (HPLC) to examine cell transformation activity. Four flasks containing 250 mL of borate-buffered fructose matrix were heated to 55°C, and the frozen cells were thawed at room temperature. Cells were centrifuged at 6500 x g and resuspended in deionized water. Two g (wet weight) of cells were mixed with the borate-buffered fructose matrix and cultured in a 1 L baffled flask at 55°C with stirring at 90 rpm. Samples were collected at 0, 1, 2, and 5 hours for HPLC analysis.
[0110] High-performance liquid chromatography (HPLC) analysis involves injecting 20 μL of 0.1% (w / v) of the test sample into the chromatographic system, using water as the mobile phase at a flow rate of 0.1 to 1.5 mL / min, and using Ca2+ with a particle size of 1 to 10 μm as the stationary phase. 2+ The resin is in the form of a column at a temperature of 80°C. C. Peaks were detected and quantified using a differential refractive index detector, and qualitatively assigned based on the retention times of known standards.
[0111] Results and Discussion Three protein sequences were detected, all of which were identified as ketose-3-epimerase proteins. For detailed sequences of these proteins, please refer to [link to relevant documentation]. Figures 1 to 3 (Sequence numbers 2, 4, and 6). The control was a xylose isomerase obtained from Clostridium cellulosum H10, which has previously been suggested to be used in the production of allulose from fructose. Its amino acid sequence is shown below. Figure 4 (Sequence number 8).
[0112] The amino acid sequences of these proteins were aligned with those of other known ketose-3-epimerases. See [link to aligned sequences]. Figure 5 Residues that are fully preserved are highlighted. These sequences contain very few conserved residues, with less than 65% of the residues being conserved between adjacent sequences.
[0113] The sequence identity of sequences numbered 2, 4, and 6 with accession numbers NP_535228 and BAA24429, and sequence number 8, was determined. The results are shown in Table 2. For each selected protein sequence, the known ketose-3-epimerase sequence identity ranged from 40% to 63%. Based on sequence alignment of all sequences, no strong overall homology was found. The selected proteins had optimized genes for expression in *E. coli* constructed and cloned into the commercially available Genscript expression vector pET15b. For each construction, transformation of *E. coli* BL21(DE3) was successful, and frozen stock samples of each strain were stored together with the expression vector. Protein expression was performed on a 1-liter scale, and whole cells were harvested as crude catalyst. Transformation activity was examined and measured using... Figure 6 %DSB allulose produced by four different test strains during the experiment was provided.
[0114] Table 2
[0115] All three hypothetical ketose-3-epimerases were successfully expressed, and all of them could successfully convert fructose into allulose, confirming that each protein is indeed a ketose-3-epimerase.
[0116] The most active protein is DS P3E (composed of...). Desmospora sp.The D-tagatose 3-epimerase obtained from 8437 (sequence number 6) can convert 30% of a 750 g / L fructose solution in just 2 hours using 8 g / L wet cell weight, with a volumetric yield of 112 g / L / hour.
[0117] Example 2 In this embodiment, current-optimal cell growth and transformation conditions were employed at an 18-liter scale to determine scalability and to produce allulose for further sensory and clinical trials. Following transformation, an initial purification step was performed to remove fructose. This embodiment aims to determine the scalability of the process, any unforeseen problems during scale-up, and the amount of allulose that can be reasonably produced in the laboratory.
[0118] materials Isopropyl galactothioglycoside (IPTG) A 100 mg / mL ampicillin aqueous solution after filtration to remove bacteria. Crystallized fructose molasses Liquid fructose (77% DS) Growth medium: i) Mix 25 grams of sodium chloride and 25 grams of Statydex ® 333, 6 grams of glycerin, 50 grams of peptone (Difco), 60 grams of yeast extract (Difco), 8 grams of dipotassium hydrogen phosphate, and 8 grams of potassium dihydrogen phosphate are dissolved in 6 liters of deionized water. ii) Adjust the pH to ~7.8 using Tris base (solid). iii) Fill six 2.8-liter flasks with baffles with 1 liter of each bottle, wrap the bottle mouths with aluminum foil, and then autoclave. 1 M pH 8 Tris buffer: iv) Dissolve 121 grams in 1 liter of deionized water iv) Adjust the pH to 8 with hydrochloric acid. iv) Store in a 1-liter bottle and then in a refrigerator at 4°C. method Ampicillin was added to six 5 mL aliquots of LB medium at a concentration of 100 μg / mL, and the cultures were incubated overnight for cell proliferation. The cultures were inoculated with *E. coli* strain BL21-DE3 pET15b-DS-P3E (expressing protein sequence number 6) and incubated at 37°C overnight (approximately 16 hours). Six liters of growth medium were prepared as described above and autoclaved. Five mL of the overnight culture was added to each flask, and the medium was shaken at 190 rpm at 37°C for 4 hours. A fresh 1 M solution was prepared, and 1 mM IPTG was added to each flask at a concentration of 1 mL / L. The mixture was cooled to 25°C and shaken for 14 to 16 hours.
[0119] Using a Model 322 floor-standing centrifuge and 1-liter flasks (filled with no more than 800 ml of culture medium), centrifuge the culture at 6000 rpm for 20 minutes to harvest cells. Pour the culture medium into a sterilizing tank, add 1% bleach by volume, and let stand for 30 minutes. Weigh the centrifuge tubes, and add 3 ml of deionized water per gram of cells. Resuspend the cells using a spatula and vortex until a homogeneous cell slurry is formed. Transfer the cell suspension to 40 ml centrifuge tubes and re-centrifuge at 6500 xg to allow sedimentation. Decant the washes into a sterilizing tank and resuspend the cells in an equal volume of water.
[0120] Repeat cell proliferation and harvesting with another batch of cells.
[0121] Heat a 5-gallon (18.9-liter) container of crystalline fructose molasses to room temperature. Add 16,506 grams of crystalline fructose molasses to a sterilized 5-gallon (18.9-liter) plastic container with an 18-liter calibration mark to prepare the crystalline fructose molasses conversion matrix. Prepare 900 ml of 1 M pH 8.0 Tris solution as described above and add it to the container. Then add water to the 18-liter calibration mark and mix thoroughly using a cantilever stirrer. Return the mixture and any unused crystalline fructose molasses to the refrigerator for storage.
[0122] In a sterilized 5-gallon (18.9-liter) plastic container marked with an 18-liter calibration label, 17,460 g of liquid fructose (77% DS) was mixed with 500 mL of 1 M pH 8.0 Tris (prepared as above) to prepare a liquid fructose conversion matrix. Water was added to the 18-liter calibration label, and the mixture was stirred thoroughly using a cantilever stirrer.
[0123] For the entire cell transformation, the prepared 18-liter crystalline fructose molasses transformation matrix was heated to 55°C in a water bath and then gently stirred with a cantilever stirrer at approximately 150 rpm. Cell paste obtained from cell harvesting was added until the total wet weight of the cells was 100 g. Samples were taken after 5 hours for high-performance liquid chromatography (HPLC) analysis. The entire container was refrigerated at 4°C to stop the reaction. One sample was taken for E. coli flora and TPC microbial analysis.
[0124] The entire cell transformation process was repeated using 18 liters of the prepared liquid fructose conversion matrix. Cells with a wet weight of 120 g were used, and samples were taken at 2 and 4 hours for high-performance liquid chromatography analysis.
[0125] Fructose was removed from the crystalline fructose molasses inversion matrix by yeast fermentation. The crystalline fructose molasses inversion product was diluted with 2 times its volume of water to achieve a combined allulose and fructose concentration of ~250 g / L in a total volume of 54 L. The 54 L diluted mixture was dispensed into four sterilized 5-gallon (18.9 L) containers, approximately 13 L each. Two of the containers were stored in the refrigerator. The remaining two containers were set to vigorous agitation with a cantilever mixer and aerated with a 9 L / min air pump equipped with a diffuser to achieve an airflow of approximately 0.3 VVM. 120 g of active dry bread yeast (Fleishman brand) was added to each container, and the mixture was agitated and aerated for 2 days (~36 h), with samples taken periodically for DP1-4 allulose analysis. The containers were then transferred to the refrigerator overnight to allow the yeast to settle. The supernatant was then collected and transferred to two new, clean, sterilized containers, and the remaining yeast was transferred to two containers containing the prepared refrigerated crystalline fructose molasses. The mixing and stirring process was repeated, followed by the removal of the yeast. After the yeast fermentation step, approximately 45 liters of supernatant were obtained and aseptically filtered into three clean and sterilized containers, then stored at 4°C for further processing.
[0126] Results and Discussion Approximately 220 g of BL21(DE3)pET-15b-DS P3E cells were obtained from 12 L of culture and divided into two fractions for the aforementioned two 18 L-scale biotransformations. Therefore, the total concentration of whole-cell biocatalyst was 5.6 g / L for crystalline fructose-molasses conversion and 6.7 g / L for liquid fructose conversion.
[0127] Figure 11 This indicates that both conversions rapidly reached ~25%, measured as allulose as a percentage of allulose + fructose. This is slightly lower than the conversion levels previously achieved on a small scale using these cells and similar conversion media, but the two are very close. When using a liquid fructose matrix, the conversion rate reached 22% in just 2 hours.
[0128] At a conversion scale of 18 liters each, approximately 3.3 kg of allulose was produced. There appeared to be no significant difference between the two matrices.
[0129] Amplification from 250 ml did not produce any unforeseen problems and proceeded as expected.
[0130] Microbiological examination results showed no live E. coli, resulting in a negative result; <3 coliforms per gram; and a total plate count of two. Therefore, a temperature of 55°C combined with a syrup with a high DS ratio was sufficient to kill whole-cell biocatalysts.
[0131] Using the newly discovered DSP3E enzyme, the bioconversion of fructose to allulose was successfully scaled up to 18 liters.
[0132] Example 3 Using a pH-controlled batch culture method and glucose yeast extract medium, two 10-liter fermentations were conducted in a fermentation laboratory to produce an *E. coli* strain containing the newly discovered DSP3E protein (number 6). Fermentation proceeded as expected.
[0133] During the fermentation batch growth and fed-batch stages, cells exhibited exponential growth, with a doubling time of approximately 1 hour. Within about 5.5 hours, glucose concentration decreased from approximately 9 g / L to <1 g / L (OD ~28). During the enzyme induction phase, OD continued to rise to approximately 130, after which no significant changes were observed. The fermentation was harvested by centrifugation, yielding 4.5 kg (10 lb) of wet cell paste, with stem cells weighing approximately 1.1 kg (2.5 lb).
[0134] The fructose matrix (836 kg, based on DS (dry solids)) was diluted to 69% DS (920 g / L) with reverse osmosis water and heated to 52°C. C, and adjusted the pH to 7.8. Low-speed stirring (approximately 50 rpm) was used throughout the reaction to promote mixing, and the entire batch of 4.5 kg (wet paste) or more of the resulting whole-cell expression was added to the reaction, with one sample taken at time 0. This provided a biocatalyst loading of 0.48 g / L, similar to previously tested laboratory-scale transformations; however, the matrix concentration was higher at 920 g / L. Samples were taken at 4 and 16 hours and analyzed by high-performance liquid chromatography.
[0135] No decrease in DS was observed during the reaction, and no bioproducts were generated. At the end of 16 hours, the reaction reached near equilibrium, approximately 30% allulose. At 4 hours, the reaction had reached 18% conversion. Previously, using 0.5 g / L biocatalyst and 750 g / L matrix (Examples 1 and 2), the volumetric conversion was 46 g / L*h, or 92 g / L*h / g biocatalyst. Here, a higher matrix concentration and a slightly lower temperature (52°C) were used. C relative to 55 (C) The volumetric conversion rate was 41 g / L*h or 85 g / L*h / g biocatalyst (calculated using data points over 4 hours). This indicates that the isomerase reaction has considerable flexibility. When the reaction was completed in 16 hours, there were 230 kg of allulose in a 28:72 allulose:fructose mixture.
[0136] Example 4 Fructose conversion using four different enzymes (sequence numbers: 2, 4, 6, 8) was compared on a 750 g / L Tris-buffered fructose matrix. At 16 C instead of 25 to 30 C induces cells, but the transformation rate is slower than in previous experiments. In a 500 mL baffled flask, 2 g of resuspended cells were added to 200 mL of matrix, and then... (The sentence is incomplete and requires more context to translate accurately.) Cultured at C and 90 rpm. Samples were collected at 2 hours and 3.5 hours for high-performance liquid chromatography analysis. Results are shown below. Figure 12 CCP3E corresponds to sequence number 8, while CH P3E, CS P3E, and DS P3E correspond to sequences numbered 4, 2, and 6, respectively. In this experiment, all four strains expressing the proteins described in sequences 2, 4, 6, or 8 showed substantially the same activity, converting approximately 5% of the matrix to allulose within 3.5 hours.
[0137] Example 5 In this embodiment, the first experiment to produce allulose was conducted using an immobilized enzyme. The purpose of this embodiment is to improve enzyme utilization.
[0138] materials Lyophilized enzyme powder prepared by Codexis, batch number: D13007 or D13008 -Desmospora sp. Allulose-3-epimerase Duolite A568 (Dow) Amberlite XAD2 (Sigma) 1 M Tris buffer: i) Prepared by dissolving in water at a concentration of 1 M. ii) Adjust the pH to 8.0 using hydrochloric acid. iii) Dilute to 100 mM before use. Crystallized fructose molasses, 80% dry solids, its composition is as follows: i) 90% DSB fructose ii) 7% DSB glucose iii) 3% DP2 + iv) Other monosaccharides MnCl2(Sigma) method 1) Small-scale fixed To test the stationary efficiency, a small fixed-bed reaction was performed in a jacketed column of approximately 30 mL (11 mm x 300 mm column size). The XAD2 and A568 resins were washed several times with water to remove fine resin particles (i.e., fine resin particles byproducts of resin preparation, i.e., broken / fragmented particles) and any residues from the manufacturing process. 2 g of lyophilized enzyme (i.e., epimerase) was dissolved in approximately 50 mL of water and divided into two aliquots. The pH was measured and found to be 6.5. Approximately 30 mL of each resin was incubated with one aliquot of the epimerase solution at room temperature with gentle stirring for approximately 1 hour. The resin was then packed into the jacketed column, and the epimerase solution was circulated through the fixed bed using a peristaltic pump for 2 hours. The column was then washed with 10 column volumes of 100 mM pH 8.0 Tris buffer. At this point, the eluent was clear and protein-free when measured spectrophotometrically on an A280. Crystallized fructose molasses was diluted to 60% DS with reverse osmosis water, then the pH was adjusted to 8.0, and then 28 ppm MnCl2 and 10 mM pH 8.0 Tris buffer were added to prepare the crystalline fructose molasses feed.
[0139] The jacketed column was heated to 57°C using a circulating water bath, and the feed was pumped through a 30 mL fixed-bed reactor at a rate of 8 bed volumes per hour (BV / h). The reactor eluent was collected and analyzed by FT-IR to provide the relative concentrations of allulose and fructose. This process lasted for 5 days. During pilot production, the feed rate was adjusted from 8 bed volumes per hour to 6 bed volumes per hour to maintain the conversion rate.
[0140] 2. Scale up to a 300 ml fixed-bed reactor To test the scale-up efficiency of the fixed bed, a large fixed-bed reactor was created using a jacketed column with a volume of approximately 300 mL (column size 25 mm x 600 mm). XAD2 and A568 resins were washed several times with water to remove fine particles and any manufacturing residues. 10 g of lyophilized epimerase was dissolved in approximately 100 mL of water. Approximately 300 mL of A568 resin was packed into a 300 mL jacketed column, and the epimerase solution was circulated through the fixed bed using a peristaltic pump for approximately 2 hours at room temperature. The column was then washed at room temperature with 5 column bed volumes of 100 mM pH 8.0 Tris buffer. At this point, the eluent was clear and protein-free when spectrophotometric determination was performed on an A280. Crystalline fructose molasses was diluted to 60% DS with reverse osmosis water, followed by pH adjustment to 8.0, and then 28 ppm MnCl2 and 10 mM pH 8.0 Tris buffer were added to prepare the crystalline fructose molasses feed. The jacketed column was heated to 57°C using a circulating water bath, and the feed was pumped through a 30 mL fixed-bed reactor at a rate of 8 column bed volumes / hour (BV / hour). The reactor eluent was collected and analyzed by FT-IR to provide the relative concentrations of allulose and fructose. This process lasted for 4 days. During pilot production, the feed rate was adjusted from 8 column bed volumes / hour to 2 column bed volumes / hour. Additionally, the column was allowed to stand at room temperature for 2 weeks before being restarted to determine the stability of the epimerase during column storage.
[0141] Results and Discussion For any test sample, no significant transformation was observed in the 30 mL column and with XAD2, therefore no further analysis was performed. However, significant transformation was detected using the Dowex A568. Figure 13 The reaction timeline is shown in a 30 mL fixed-bed reactor with A568 resin. Over 4 kg of allulose was produced during a 120-hour fixed-bed conversion using only 1 gram of epimerase. The percentage conversion gradually decreased over the 120 hours, therefore the column flow rate was reduced at 72 hours to compensate for the decrease in conversion. A near-equilibrium allulose concentration was achieved during the reaction.
[0142] Figure 14 The diagram shows a 300 mL reaction process using A568 resin. Due to feed limitations (86 L feed over 72 hours), the flow rate was reduced at 24 hours. Over 20 kg of allulose was produced from 10 g of epimerase within 72 hours. At the end of 72 hours, the conversion rate remained high, although a slight decrease in performance was observed.
[0143] The stability of epimerases in solution has been previously determined in flask reactions. At 53°C, over 90% of the activity was lost within 8 hours. In this example, the transformation was performed at 57°C. The advantages of the higher temperature are in the reaction rate, equilibrium ratio, and microbial stability. In this example, significant epimerase activity was maintained even after 120 hours.
[0144] In large-scale reactions with limited feed, 10 g of epimerase produced 20 kg of allulose, resulting in a net epimerase feed ratio of 0.05% (mass / mass). In small-scale reactions, 1 g of epimerase produced 4.8 kg of allulose, resulting in a net epimerase feed ratio of 0.02% (mass / mass). In standard fructose production, immobilized glucose epimerase was used at a rate of 0.01% to 0.005% (mass / %) over an operation period of 6 to 12 months.
Claims
1. A protein comprising a polypeptide sequence having 90-95% sequence identity with sequence number 6, characterized in that, This protein possesses allulose-3-epimerase activity.
2. The protein according to claim 1, characterized in that, The protein is immobilized in a solid matrix.
3. The use of protein in the synthesis of allulose, characterized in that, The polypeptide sequence of this protein has 90-95% sequence identity with sequence number 6, and the protein has allulose-3-epimerase activity.
4. A nucleic acid molecule comprising a polynucleotide sequence encoding the protein of claim 1 or 2.
5. The nucleic acid molecule according to claim 4, wherein the nucleic acid molecule comprises a polynucleotide sequence, characterized in that: (i) It has 90-95% sequence identity with sequence number 5; or (ii) A polynucleotide was obtained by hybridization under highly stringent conditions, which has a sequence complementary to the sequence shown in number 5; in, The polynucleotide sequence is different from sequence number 5.
6. A vector comprising a nucleic acid molecule according to claim 4 or 5.
7. A host cell comprising a nucleic acid molecule according to claim 4 or 5.
8. The host cell according to claim 7, wherein, The host cell is yeast, bacteria or other microorganisms, or a culture of mammals, plants or other cells.
9. The host cell according to claim 8, wherein, The host cell is Escherichia coli.
10. A method for manufacturing allulose, characterized in that, The method includes contacting a protein with a fructose matrix under conditions that allow the fructose matrix to be converted into allulose, wherein the polypeptide sequence of the protein has 90-95% sequence identity with sequence number 6, and the protein has allulose-3-epimerase activity.
11. The method according to claim 10, characterized in that, This protein is present in the host cell.
12. The method according to claim 10, characterized in that, The protein is in isolated form.
13. The method according to any one of claims 10-12, wherein the conditions include maintaining the protein and fructose matrix between 25°C and 75°C.
14. The method according to any one of claims 10-12, wherein the conditions include maintaining the protein and fructose matrix between pH 4 and pH 10.
15. The method according to any one of claims 10-12, wherein the condition comprises maintaining the concentration of the fructose matrix between 75% and 95% (weight / volume).
16. A nucleic acid molecule comprising a polynucleotide sequence, the polynucleotide sequence being characterized in that: (i) Has 90-95% sequence identity with number 5; or (ii) A polynucleotide is obtained by hybridization under highly stringent conditions, the polynucleotide having a sequence complementary to the sequence shown in number 5; in, The polynucleotide sequence is different from sequence number 5.
17. A host cell comprising a recombinant nucleic acid molecule containing a polynucleotide sequence encoding a polypeptide having allulose-3-epimerase activity, the polynucleotide sequence being characterized in that: (i) Has 90-95% sequence identity with number 5; or (ii) A polynucleotide was obtained by hybridization under highly stringent conditions, which has a sequence complementary to the sequence shown in number 5; The polynucleotide sequence is different from the sequence numbered 5.
18. A vector comprising a nucleic acid molecule containing a polynucleotide encoding a polypeptide having allulose-3-epimerase activity, wherein the polynucleotide sequence is characterized by: (i) Has 90-95% sequence identity with number 5; or (ii) A polynucleotide was obtained by hybridization under highly stringent conditions, which has a sequence complementary to the sequence shown in number 5; in, The polynucleotide sequence is different from sequence number 5.
19. A method for manufacturing allulose, the method comprising the following steps: (i) Provides a vector containing a nucleic acid molecule having a polynucleotide sequence encoding a protein having allulose-3-epimerase activity, wherein the polynucleotide sequence is characterized in that: (a) it has 90-95% sequence identity with the sequence numbered 5; or (b) the polynucleotide is obtained by hybridization under highly stringent conditions having a sequence complementary to the sequence shown in numbered 5; (ii) Synthesize a protein with allulose-3-epimerase activity encoded by a polynucleotide sequence; (iii) Contacting fructose with a protein possessing allulose-3-epimerase activity, and maintaining the fructose and protein under conditions that allow the fructose to be converted into allulose; and (iv) At least partially purify the allulose produced in step (iii).
Citation Information
Patent Citations
Novel Sinorhizobium sp. YB-58 strain converting fructose into psicose, and method for producing psicose using the same strain
KR100832339B1
Housing device of wireless communication apparatus
KR1020090098938A
Ketose 3-epimerase, its preparation and uses
US20110275138A1
D-psicose production method by D-psicose epimerase
US8030035B2
Immobilization of psicose-epimerase and a method of producing d-psicose using the same
WO2011040708A2
